Jan A. Alfheim, Oncoinvent CEO commented, ‘We are very pleased to have accomplished this important milestone in such a short time after the inauguration of our production facility. The approval provides Oncoinvent with the necessary capacity and flexibility with full control over the production of clinical trial material of Radspherin® for the upcoming clinical studies expected to start later this year. After having sent in the clinical trial application earlier this month the company is now fully prepared to start the clinical development of Radspherin®’
For further information, please contact:
Jan A. Alfheim,
Chief Executive Officer
Chief Financial Officer
This information was brought to you by Cision http://news.cision.com
STOCKHOLM, Feb. 19, 2019 /PRNewswire/ — Oncoinvent is pleased to announce that it has received a manufacturing authorization (GMP certificate) for production of Radspherin® clinical trial material from the Norwegian Medicine Agency.